PeptidesEvidence ReviewAug 2026

Best Peptides for Women in 2026

For each peptide marketed to women, this page reports the human studies behind it: who was enrolled, what was measured, what the paper found. Every citation was retrieved through NCBI E-utilities on 9 August 2026. Some trials recruited women and nobody else, some publish a sex breakdown, some report by arm. The population column is where that shows.

1,267

Women randomised in the bremelanotide phase 3 trials (PMID 31599840)

2,463

Postmenopausal women in the abaloparatide ACTIVE trial (PMID 27533157)

7,847

Adults in the GLP-1 sex-difference cohort (PMID 40706779)

The Studies

One row per study, not one per compound. A compound studied four times gets four rows, because those papers asked different questions in different people.

Compound	Population (n)	What was measured	Result	Design	PMID
Bremelanotide	1,267 premenopausal women with hypoactive sexual desire disorder, mean age 39	Female Sexual Function Index desire domain and Female Sexual Distress Scale item 13	Desire +0.35 and distress -0.33 versus placebo, both P below .001	Two identical randomised double-blind placebo-controlled phase 3 trials, 24 weeks	31599840
Kisspeptin-54	40 premenopausal women with hypoactive sexual desire disorder, 32 completed	Brain response to erotic and facial attraction stimuli on functional imaging	Modulated activity in inferior frontal gyrus (P = .01), postcentral and supramarginal gyrus (P below .001) and temporoparietal junction (P = .02)	Randomised double-masked placebo-controlled crossover, one infusion	36287566
Teriparatide, parathyroid hormone 1 to 34	1,637 postmenopausal women with prior vertebral fractures	New vertebral fractures over a median 21 months	14 percent on placebo versus 5 and 4 percent on the two active arms; relative risks 0.35 (95 percent CI 0.22 to 0.55) and 0.31 (0.19 to 0.50)	Randomised placebo-controlled, daily subcutaneous injection	11346808
Abaloparatide	2,463 postmenopausal women with osteoporosis, mean age 69	New morphometric vertebral fracture; hypercalcaemia against teriparatide	Fewer new vertebral fractures than placebo and larger bone density gains, all P below .001. Hypercalcaemia 3.4 versus 6.4 percent, P = .006. Fracture percentages sit in a table, not the abstract	Phase 3 double-blind randomised trial, 18 months	27533157
Semaglutide plus metformin	100 overweight or obese women with polycystic ovary syndrome, 80 completed	Body weight at week 16; natural pregnancy in weeks 16 to 40, both arms on metformin alone	6.09 kg lost versus 2.25 kg on metformin alone, P below .01. Pregnancy 35 versus 15 percent, P below .05	Prospective randomised controlled open-label trial, single hospital	40713699
Hydrolysed collagen, oral	1,125 participants aged 20 to 70 pooled from 19 trials, 95 percent women	Skin hydration, elasticity and wrinkles	Favoured collagen over placebo on all three; hydration and elasticity held in subgroup analysis	Meta-analysis of randomised double-blind controlled trials	33742704
GLP-1 receptor agonists as a class	7,847 adults with type 2 diabetes at 18 Italian centres, 60 percent male	Weight change by self-reported sex over a median 4 years	Females 1.1 kg below males on adjustment, P below 0.001. A 5 percent loss reached by 66.5 versus 58.0 percent	Retrospective longitudinal real-world cohort	40706779
Tirzepatide with a combined oral contraceptive	An interaction study summarised in a 2025 review, which does not state n	Peak concentration and total exposure of ethinylestradiol and norelgestromin	Ethinylestradiol ratios 0.41 and 0.79; norelgestromin 0.45 and 0.78, against a no-change band of 0.8 to 1.25	Single-dose pharmacokinetic interaction study, from Table 4 of a review	40330819
Liraglutide, exercise, or both	195 adults with obesity aged 18 to 65, 124 female and 71 male	Bone mineral density at hip, spine and forearm after diet plus 52 weeks of treatment	Combination against placebo at the hip -0.006 g/cm2 (95 percent CI -0.017 to 0.004), P = .24. Liraglutide against exercise -0.013 (-0.024 to -0.001), P = .03	Predefined secondary analysis of a randomised trial, called exploratory by its authors	38916894
GLP-1 receptor agonists around conception	938 exposed infants of women with type 2 diabetes, against 5,078 insulin-exposed infants	Major congenital malformations, followed to one year	8.3 versus 7.8 percent on insulin; adjusted relative risk 0.95 (95 percent CI 0.72 to 1.26). Standardised prevalence 5.3 percent in infants of women with type 2 diabetes, 3.7 percent in all infants	Observational population-based cohort, Nordic, US and Israeli data	38079178
Copper tripeptide 1, inside the QR678 formulation	20 women aged 25 to 50 with polycystic ovary syndrome and female pattern alopecia	Vellus and terminal hair counts and shaft diameter, by videomicroscopy	After eight sessions, 11.66 fewer vellus hairs, 13.77 more terminal hairs and shafts 2.86 micrometres wider	Prospective single-arm study, eight intradermal sessions	33460214
Copper tripeptide complex skin care	13 patients who completed the study after carbon dioxide laser resurfacing	Erythema, wrinkles and skin quality by blinded evaluators, plus a patient questionnaire	Blinded evaluators found no significant difference between groups. The patient questionnaire favoured the copper tripeptide regimen, P = .04	Randomised post-treatment regimens with blinded evaluation	16847171
Thymosin beta-4 eye drops	9 patients with severe dry eye at 2 US sites	Ocular discomfort on the OSDI questionnaire and corneal fluorescein staining, day 56	35.1 percent less discomfort (P = 0.0141) and 59.1 percent less staining (P = 0.0108) than vehicle control	Randomised double-masked placebo-controlled phase 2 trial, 56 days	25826322
Thymosin beta-4, measured rather than administered	87 women in various clinical states, including postmenopausal and castrated	Basal circulating thymosin beta-4 and alpha 1 by radioimmunoassay	Beta-4 reduced in castrated women not receiving oestrogen, reduced further on chronic oestrogen therapy. Alpha 1 similar across groups	Cross-sectional radioimmunoassay study	2983555
BPC-157, intravenous	2 adults at a private clinic in Florida, a man of 58 and a woman of 68	Heart, liver, kidney and thyroid biomarkers, blood glucose, side effects	No measurable effects on the tested biomarkers and no side effects reported	Open-label pilot study, single site, three days	40131143

Every Participant Was Female

RECONNECT and the kisspeptin crossover both studied hypoactive sexual desire disorder in premenopausal women, with different endpoints: a questionnaire score in one, brain imaging in the other. The fracture trials studied postmenopausal osteoporosis and counted radiographic fractures rather than a surrogate marker. The polycystic ovary syndrome trial collected its pregnancy comparison after semaglutide had stopped. Background sits on the PT-141 page, and the life-stage angle on the menopause and perimenopause guide.

The regimens those trials administered, each named with its paper:

Bremelanotide 1.75 mg subcutaneously as needed over 24 weeks (PMID 31599840). Kisspeptin-54 infused at 1 nmol per kg per hour for 75 minutes (PMID 36287566). Parathyroid hormone 1 to 34 at 20 or 40 micrograms daily by subcutaneous injection (PMID 11346808). Abaloparatide 80 micrograms daily against open-label teriparatide 20 micrograms daily, 18 months (PMID 27533157). Metformin 1000 mg twice daily, with or without semaglutide 1 mg once weekly, 16 weeks (PMID 40713699).

Disclaimer: these are trial arms reported for comparison, not recommendations and not a titration schedule. Each is a prescription decision made with a doctor.

Where A Sex Breakdown Exists

The pooled collagen review states that its 1,125 participants were 95 percent women, so the claims printed on a tub were largely measured in female skin; formulation questions sit on the collagen peptides guide. The Italian cohort compared the sexes directly, which is what searches for the best weight loss peptides for women are reaching for: over a median four years, women lost 1.1 kg more than men on adjustment. Read that size beside its significance, because it is a small gap on a much larger effect both sexes recorded, in a retrospective cohort where everyone had type 2 diabetes. Tolerability sits on the GLP-1 side effects guide, the molecule comparison on the tirzepatide versus semaglutide page, and skin during rapid loss on the loose skin guide.

The Contraceptive Interaction

Delayed gastric emptying slows absorption of a swallowed pill, and one interaction study collected in the 2025 review measured how far that goes. After a single dose of tirzepatide with a combined oral contraceptive, peak ethinylestradiol concentration fell 59 percent and total exposure 21 percent, with norelgestromin down 55 and 22 percent, against the no-change band of 0.8 to 1.25 the review works to. The investigators suggested a non-oral option or a barrier method for 4 weeks after tirzepatide is started or substantially increased.

From that review (Min et al., Drug Design, Development and Therapy, 2025, PMID 40330819), the interaction study used:

A single 5 mg dose of tirzepatide, given with a combined oral contraceptive.

Disclaimer: a single-dose pharmacokinetic figure, reported so the size of the change is visible, not a recommendation. Nobody should start, change or stop a contraceptive method from a web page.

Pregnancy And Preconception

That cohort covered women with type 2 diabetes who filled a prescription between 90 days before pregnancy and the end of the first trimester. Quoting its 8.3 percent malformation figure without the comparators would mislead, and the interval around the adjusted relative risk of 0.95 runs from 0.72 to 1.26, compatible with a reduction and with a 26 percent increase. The authors called some estimates imprecise. Pregnancy, breastfeeding and preconception are doctor conversations.

Reported By Treatment Arm

Several rows above report outcomes by arm rather than by sex: patients with severe dry eye, patients after laser resurfacing, and two adults given an intravenous infusion at a private clinic. The 1985 radioimmunoassay study works differently, because it measured circulating thymosin beta-4 in 87 women instead of administering anything, so it poses a question about oestrogen and this peptide rather than answering one. Background sits on the BPC-157, TB-500 and GHK-Cu pages, and what to check before buying anything on the COA verification guide.

How These Records Were Found

Each line states a query, an index and a date. A search result describes what a string matched in one database on one day, nothing beyond that.

BPC 157 in PubMed on 9 August 2026 returned 225 records.
BPC 157 AND clinical trial[pt] in PubMed on 9 August 2026 returned 0 records; the publication tag is the boundary of that count.
BPC 157 AND (women OR female OR menstrual OR pregnancy) in PubMed on 9 August 2026 returned 22 records, among them PMID 40131143.
thymosin beta 4 AND clinical trial[pt] in PubMed on 9 August 2026 returned 8 records.
(GHK-Cu OR copper tripeptide) AND clinical trial[pt] in PubMed on 9 August 2026 returned 4 records. PMID 33460214 carries no such tag and sits outside that count.
CJC-1295 AND clinical trial[pt] and ipamorelin AND clinical trial[pt] each returned 2 records in PubMed on 9 August 2026.
kisspeptin AND women AND randomized controlled trial[pt] in PubMed on 9 August 2026 returned 14 records.
(BPC 157 OR TB-500 OR thymosin beta 4 OR GHK-Cu OR copper tripeptide OR CJC-1295 OR ipamorelin) AND (menstrual cycle OR contraception OR perimenopause OR hormonal contraceptive) in PubMed on 9 August 2026 returned 1 record, PMID 2983555.
(BPC 157 OR TB-500 OR GHK-Cu OR CJC-1295 OR ipamorelin) AND pregnancy in PubMed on 9 August 2026 returned 2 records, PMID 1748624 and PMID 4066687, both cell-culture papers.
sermorelin in PubMed on 9 August 2026 returned 331 records, and PMID 11816525, a growth hormone releasing hormone study in menopausal women, is not among them. A compound name bounds a search, so names, synonyms and MeSH entry terms were tried where known.

Frequently Asked Questions

What are the best peptides for women?+

This page does not rank them. It reports what each cited study enrolled, what it measured and what it found, so a fracture count in 1,637 postmenopausal women and a biomarker panel in 2 adults can be told apart. Reading the population column first shows which claims were measured in women and which were measured in someone else.

Does it matter whether a trial enrolled women or simply included them?+

It changes what the number applies to. A trial recruiting only postmenopausal women with prior vertebral fractures produced a result in postmenopausal women with prior vertebral fractures. A mixed-sex trial publishing no sex breakdown produced a result in its whole sample, and splitting that sample afterwards is a separate exercise carrying wider uncertainty.

Can a GLP-1 receptor agonist change how a contraceptive pill is absorbed?+

These drugs slow gastric emptying, so a swallowed pill can be absorbed more slowly, and the size of that effect differs between molecules. The 2025 review by Min and colleagues (PMID 40330819) reports that oral and subcutaneous semaglutide left ethinylestradiol and levonorgestrel inside its 0.8 to 1.25 no-change band. It adds that delayed gastric emptying shows tachyphylaxis, fading over time, and that the relationship between contraceptive exposure and contraceptive effect is not yet fully defined. Contraception is a decision for a doctor or pharmacist who knows the method being used.

Does the hair result from QR678 belong to copper tripeptide?+

It belongs to the formulation. A companion paper from the same group (PMID 32983753) states that QR678 suspends vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor 1, keratinocyte growth factor and copper tripeptide 1 in an injectable vehicle. The trial in women with polycystic ovary syndrome injected that mixture, and its design carried no control arm.

Why does the same compound appear in more than one row?+

Because a row is a study, not a compound. Thymosin beta-4 appears as an eye drop trial in severe dry eye and as a hormone measured in blood samples from women, two papers answering unrelated questions. Collapsing them into one verdict loses the population and the endpoint that made each result mean something.

What should someone take to a doctor after reading this?+

The population and the endpoint, not the compound name. Every regimen printed above was administered under medical supervision inside its trial, and polycystic ovary syndrome, osteoporosis and hypoactive sexual desire disorder are diagnoses made by a clinician. If you are pregnant, breastfeeding, trying to conceive or using hormonal contraception, those facts belong in the conversation.

Research And Sources

Every figure above comes from the record its PMID links to, retrieved through NCBI E-utilities on 9 August 2026. Where a number was not in the abstract, the full text was read through Europe PMC: the tirzepatide contraceptive ratios come from Table 4 of the Min review, read as PMC12052016. The QR678 composition quoted in the FAQ comes from PMID 32983753.